{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T09:47:15Z","timestamp":1782726435776,"version":"3.54.5"},"reference-count":28,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"GlaxoSmithKline","award":["221792"],"award-info":[{"award-number":["221792"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"DOI":"10.1080\/14737167.2026.2693168","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T07:33:07Z","timestamp":1782372787000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Single versus multiple inhaler triple therapy in COPD using data from the pragmatic INTREPID trial: cost-effectiveness analysis from the Chilean public healthcare system perspective"],"prefix":"10.1080","author":[{"given":"Felipe Moraes","family":"dos Santos","sequence":"first","affiliation":[{"name":"GSK","place":["Santiago, Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00e1s","family":"Sandoval Astudillo","sequence":"additional","affiliation":[{"name":"GSK","place":["Santiago, Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Espinoza","sequence":"additional","affiliation":[{"name":"Pontificia Universidad Cat\u00f3lica de Chile","place":["Santiago, Chile"]},{"name":"Epsilon Research","place":["Santiago, Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Balmaceda","sequence":"additional","affiliation":[{"name":"Pontificia Universidad Cat\u00f3lica de Chile","place":["Santiago, Chile"]},{"name":"Epsilon Research","place":["Santiago, Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Fernando Romero","sequence":"additional","affiliation":[{"name":"GSK","place":["Santiago, Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen G.","family":"Noorduyn","sequence":"additional","affiliation":[{"name":"GSK","place":["Mississauga, Canada"]},{"name":"McMaster University","place":["Hamilton, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"e_1_3_6_3_1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease [Internet]. 2026 [cited 2026 Mar 30]. Available from: https:\/\/goldcopd.org\/2026-gold-report-and-pocket-guide\/"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67632-5"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.4067\/S0717-73482017000400284"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(23)00217-6"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S370540"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00950-2020"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X16653118"},{"key":"e_1_3_6_10_1","unstructured":"Ministerio de Salud (Chile). Unidad de Evaluaciones de Tecnolog\u00edas Sanitarias. Gu\u00eda metodol\u00f3gica para la evaluaci\u00f3n econ\u00f3mica de intervenciones en salud en Chile [Internet]. Santiago: Ministerio de Salud; 2021 [cited 2026 Feb 26]. Available from: https:\/\/etesa-sbe.minsal.cl\/wp-content\/uploads\/2022\/06\/Gu\u00eda-Metodol\u00f3gica-Impacto-Presupuestario-16_12_2021_FINAL.pdf"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2010.09.011"},{"key":"e_1_3_6_12_1","volume-title":"The IMPACT trial: single inhaler triple therapy versus dual therapies: efficacy across multiple COPD endpoints over time","author":"Lipson DA","year":"2019","unstructured":"Lipson DA, Criner G, Dransfield M, et al. The IMPACT trial: single inhaler triple therapy versus dual therapies: efficacy across multiple COPD endpoints over time. Madrid (Spain): European Respiratory Society International Congress; 2019."},{"issue":"4","key":"e_1_3_6_13_1","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1164\/rccm.201703-0449OC","article-title":"Once-daily single-inhaler triple therapy in patients with chronic obstructive pulmonary disease (FULFIL trial)","volume":"196","author":"Lipson DA","year":"2017","unstructured":"Lipson DA, Barnacle H, Birk R, et al. Once-daily single-inhaler triple therapy in patients with chronic obstructive pulmonary disease (FULFIL trial). Am J Respir Crit Care Med. 2017;196(4):438\u2013446.","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S370577"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S216072"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S400707"},{"issue":"5","key":"e_1_3_6_17_1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1080\/14737167.2022.2044308","article-title":"Cost-effectiveness analysis of fluticasone furoate\/umeclidinium\/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health system","volume":"22","author":"Balmaceda C","year":"2022","unstructured":"Balmaceda C, Espinoza MA, Abbott T, et al. Cost-effectiveness analysis of fluticasone furoate\/umeclidinium\/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health system. Expert Rev Pharmacoecon Outcomes Res. 2022;22(5):743\u2013751.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.4067\/s0717-73482024000400234"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.4067\/s0717-73482025000300182"},{"key":"e_1_3_6_20_1","unstructured":"Cenabast. Lista de medicamentos \u2013 Ley Cenabast [Internet]. Santiago: Central de Abastecimiento del Sistema Nacional de Servicios de Salud; [cited 2024 Sep 23]. Available from: https:\/\/www.cenabast.cl\/lista-de-medicamentos-ley-cenabast\/"},{"key":"e_1_3_6_21_1","unstructured":"Central Bank of Chile. Base de datos estad\u00edsticos (BDE) [Internet]. Santiago: Banco Central de Chile; [cited 2026 Feb 26]. Available from: https:\/\/www.bcentral.cl"},{"key":"e_1_3_6_22_1","unstructured":"Instituto de Administraci\u00f3n de Salud. Estudio del costo individual promedio por beneficiario del conjunto priorizado de problemas de salud con garant\u00edas expl\u00edcitas (EVC-2021) [Internet]. Santiago: Ministerio de Salud; [cited 2026 Feb 26]. Available from: http:\/\/desal.minsal.cl\/publicaciones\/apoyo-reforma-ges\/"},{"key":"e_1_3_6_23_1","unstructured":"Chile. Fondo Nacional de Salud. Resoluci\u00f3n Exenta N\u00b0 66 que aprueba el procedimiento para el c\u00e1lculo de los recursos establecidos en el Programa 05 \u201cFinanciamiento Hospitales por GRD\u201d [Internet]. Santiago: Fondo Nacional de Salud; 2022 [cited 2025 May 21]. Available from: https:\/\/assets.clapesuc.cl\/Mecanismo_GRD_17_Nov_final_v2_e4d6520d7f.pdf"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X15610781"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-11-122"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00111707"},{"key":"e_1_3_6_27_1","unstructured":"Banco Central de Chile. Base de datos estad\u00edsticos (BDE) [Internet]. Santiago: Banco Central de Chile; 2025 [cited 2025 May 19]. Available from: https:\/\/si3.bcentral.cl\/Siete\/ES\/Siete\/Cuadro\/CAP_ESTADIST_MACRO\/MN_EST_MACRO_IV\/PEM_ACTyDDA_IndMacA_2_2018\/637807928386827498"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2018.1443810"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S423993"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02776-8"}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2026.2693168","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14737167.2026.2693168","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2026.2693168","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T09:27:46Z","timestamp":1782725266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737167.2026.2693168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":28,"alternative-id":["10.1080\/14737167.2026.2693168"],"URL":"https:\/\/doi.org\/10.1080\/14737167.2026.2693168","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"value":"1473-7167","type":"print"},{"value":"1744-8379","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-09-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}